biostudies-literatureGrillo PThe Marlene and Paolo Fresco Institute Post-doctoral Clinical FellowshipNEXTGENERATIONEU (NGEU)Michael J Fox Foundation, Parkinson's Foundation, Department of DefenseNINDS NIH HHSNational Recovery and Resilience Plan (NRRP)National Institutes of HealthMinistry of University and Research (MUR)NextGenerationEUMinistero dell&apos;Università e della RicercaNIH HHS305-314https://www.ebi.ac.uk/biostudies/studies/S-EPMC11904876biostudies-literatureUnknown40(2)<h4>Background</h4>α-Synuclein seed amplification assay on cerebrospinal fluid (CSF-αSyn-SAA) has shown high accuracy for Parkinson's disease (PD) diagnosis. The analysis of CSF-αSyn-SAA parameters may provide useful insight to dissect the heterogeneity of synucleinopathies.<h4>Objective</h4>To assess differences in CSF-αSyn-SAA amplification parameters in participants with PD stratified by rapid eye movement (REM) sleep behavior disorder (RBD), dysautonomia, GBA, and LRRK2 variants.<h4>Methods</h4>Clinical and CSF-αSyn-SAA data from the Parkinson's Progression Marker Initiative dataset were used. CSF-αSyn-SAA parameters included maximum fluorescence (F_max), time to reach 50% of F_max (T50), time to threshold (TTT), slope, and area under the curve (AUC). Sporadic PD (nMovement disorders : official journal of the Movement Disorder SocietyAssociation between the Amplification Parameters of the α-Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease.PMC11904876U01 NS113851MNESYS (PE0000006)R56 NS131658R01 NS131658RF1 NS126406PD210038U01 NS122419R01 NS133742R01 NS116006Kang UJConcha-Marambio LRiboldi GMPisani AGrillo PfalseAssociation between the Amplification Parameters of the α-Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease.<h4>Background</h4>α-Synuclein seed amplification assay on cerebrospinal fluid (CSF-αSyn-SAA) has shown high accuracy for Parkinson's disease (PD) diagnosis. The analysis of CSF-αSyn-SAA parameters may provide useful insight to dissect the heterogeneity of synucleinopathies.<h4>Objective</h4>To assess differences in CSF-αSyn-SAA amplification parameters in participants with PD stratified by rapid eye movement (REM) sleep behavior disorder (RBD), dysautonomia, GBA, and LRRK2 variants.<h4>Methods</h4>Clinical and CSF-αSyn-SAA data from the Parkinson's Progression Marker Initiative dataset were used. CSF-αSyn-SAA parameters included maximum fluorescence (F_max), time to reach 50% of F_max (T50), time to threshold (TTT), slope, and area under the curve (AUC). Sporadic PD (n2025-01-01T00:00:00Z2025 Feb2026-06-12T10:19:18.189Z2026-06-12T03:11:49.649ZS-EPMC119048763969228310.1002/mds.30085